Etravirine (TMC-125) is an drug currently under investigation for the treatment of HIV. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTIs). Unlike the currently available agents in the class, resistance to other NNRTIs does not seem to confer resistance to entravirine. Etravirine is being developed by Tibotec, a subsidiary of Johnson & Johnson. The Food and Drug Administration is scheduled to review the safety and efficacy data for etravirine in early 2008.
- ↑ Stellbrink HJ. Antiviral drugs in the treatment of AIDS: what is in the pipeline? Eur J Med Res. 2007 Oct 15;12(9):483-95. PMID: 17933730
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies